Skip to content
Triptorelin (Trelstar, Decapeptyl) / Studies
Synthetic analog · 10 amino acids · 1,311.4 Da

Triptorelin (Trelstar, Decapeptyl) studies and research data

PepBank has 345 triptorelin studies with results. 270 of them gave triptorelin, with 1,338 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 1,338 results and 900 papers. Newer studies from Europe PMC

Results in people
1,050
78% of 1,338 results
Results in animals
256
19% of 1,338 results
Results in lab cells
32
2% of 1,338 results
From computer models
0
0% of 1,338 results
The molecule

Triptorelin identity

Identifiers, parent molecule, targets and development stage, from curated data.

Triptorelin is a GnRH decapeptide analog with D-tryptophan at position 6, N-terminal pyroglutamate, and C-terminal glycinamide. Trelstar contains the pamoate salt. Other products contain acetate. It is distinct from gonadorelin and other GnRH agonists.

Kind
Synthetic analog · 10 residues
Identifiers
UniProtP01148 (opens in a new tab)PubChem CID25074470 (opens in a new tab)UNII9081Y98W2V (opens in a new tab)DrugBankDB06825 (opens in a new tab)CAS57773-63-4
Parent
Analog of Gonadorelin · residues 24-33Triptorelin replaces GnRH Gly6 with D-Trp. The native decapeptide occupies UniProt P01148 residues 24-33.
Development
Approved in the US and EU (Trelstar)Multiple developers and marketing holdersAn approved medicinal product exists. Investigational indications and formulations have separate development status. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
TargetActionEvidence
Gonadotropin-releasing hormone receptorGNRHRP30968 (opens in a new tab)Agonistofficial prescribing informationSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

10 amino acids · 3 modifications

Residues 1 to 10:
HWSYLRPG
  • HydrophobicA V I L M
  • AromaticF W Y
  • PositiveK R H
  • PolarS T N Q
  • SpecialC G P
  • Modified residue

Modifications

10
C-terminal amide
C-terminal carboxamide.
6
D-amino acid
D-tryptophan replaces native Gly6.
1
Cyclization
The N-terminal Q representation denotes pyroglutamate after cyclization.

Alignment to Gonadorelin

Calculated from the two sequences. Curated notes are shown as given.

8 of 10 aligned residues identical (80%) · 1 substitution · 1 non-canonical residue · 1 modified residue · Gonadorelin 1–10

  • Top row: Gonadorelin (parent)
  • Bottom row: Triptorelin (Trelstar, Decapeptyl)
HWSYLRP
  • Same as parent
  • Substituted
  • Non-canonical or D-form
  • Added
  • Gap
  • Modified side chain or end

Differences from the parent

  1. 1Parent 1 · analog 1Xaa → Gln · SubstitutionThe N-terminal Q representation denotes pyroglutamate after cyclization.
  2. 2Parent 6 · analog 6Gly → D-Trp · D-amino acidD-tryptophan D-tryptophan replaces native Gly6.
  3. 3Parent 10 · analog 10Gly, modified · C-terminal amideC-terminal carboxamide.

Basis: Triptorelin replaces GnRH Gly6 with D-Trp. The native decapeptide occupies UniProt P01148 residues 24-33.

Calculated from the two sequences with @pepdb/chem alignToParent (ungapped unless a gap scores higher). The record’s curated notes are shown as given.

Properties

From identity sources

Formula
C64H82N18O13
Molecular weight
1,311.4 g/mol
Monoisotopic mass
1,310.6309 Da

Calculated from the sequence

Some values cannot be calculated. A modification changes this value and is not modeled here (for example a lipid, metal or linker).

Average mass
Not calculated
Monoisotopic mass
Not calculated
Isoelectric point (pI)
Not calculated
Net charge at pH 7.4
Not calculated
GRAVY (hydropathy)
−1.330
Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982
Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced)
12,490 M⁻¹ cm⁻¹
5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
Instability index
46.61
Dipeptide instability weights (DIWV) · Guruprasad et al. 1990
Above 40: classed as possibly unstable (ExPASy).
Aliphatic index
39.0
Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index
1.81 kcal/mol
Mean solubility value (negated) · Boman 2003
2.48 or below: lower protein-binding potential (Boman).
Hydrophobic moment (μH)
Not calculated
The sequence is too short for this method.
  • Not included: cyclization. Mass, charge and pI are not calculated; use the identity-source values.
  • The N-terminal group is not modeled.
  • D-amino acids have the same mass and charge as L forms. Hydrophobicity scales were measured on L forms.
  • Defined and validated for proteins; use with care for short peptides.
  • Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

No charge curve

A modification changes this value and is not modeled here (for example a lipid, metal or linker).

Composition

  • Hydrophobic10% (1)
  • Aromatic30% (3)
  • Positive20% (2)
  • Polar20% (2)
  • Special20% (2)

10 residues. Each residue counts in one class; F and W count as aromatic.

A Ala0 · 0%
I Ile0 · 0%
L Leu1 · 10%
M Met0 · 0%
V Val0 · 0%
F Phe0 · 0%
W Trp2 · 20%
Y Tyr1 · 10%
H His1 · 10%
K Lys0 · 0%
R Arg1 · 10%
D Asp0 · 0%
E Glu0 · 0%
N Asn0 · 0%
Q Gln1 · 10%
S Ser1 · 10%
T Thr0 · 0%
C Cys0 · 0%
G Gly1 · 10%
P Pro1 · 10%

3D structure

PredictedAlphaFold DB · P01148

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

  • Very high (pLDDT > 90)
  • Confident (90 > pLDDT > 70)
  • Low (70 > pLDDT > 50)
  • Very low (pLDDT < 50)

Predicted model of the whole UniProt entry P01148, not an experimental structure of Triptorelin (Trelstar, Decapeptyl). Triptorelin (Trelstar, Decapeptyl) = residues 24–33.

AlphaFold DB, EMBL-EBI and Google DeepMind · CC BY 4.0

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 25074470(opens in a new tab)

CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)[C@@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8
Results by area

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Trials and papers
Status and safety
Data